May 15, 2020
Transgene, NEC algorithm looks accurate in spotting cancer mutations
T G4050 is being evaluated in two Phase 1 clinical trials. It combines Transgene’s proprietary myvac® platform with NEC’s cutting-edge…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: oncology
May 15, 2020
Nimbus finds potent and selective anti-tumor HPK1 inhibitorin preclinical models
These data support the potential of our HPK1 inhibitor to alter the tumor microenvironment to halt cancer’s immune evasion, which we think could be a powerful tool in today’s immuno-oncology arsenal.
May 11, 2020
Lynparza approved in US as with bevacizumab for HRD-positive advanced ovarian cancer
AstraZeneca’s and Merck’s Olaparib, Lynparza has been approved in US as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer, the companies said Monday in a press release.
May 11, 2020
BMS Research at ASCO shows approaches in treating cancer
Bristol Myers Squib has presented a wide range of research platforms across immunotherapy, cell therapy and protein degradation underscore commitment to advancing cancer research and treatments.
May 7, 2020
Canbridge gets marketing approval of Nerlynx in China
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that its licensing partner CANbridge Pharmaceuticals, Inc. has received marketing approval of NERLYNX® (neratinib) in mainland China from the National Medical Products Administration (NMPA) of China.
May 6, 2020
Nanobiotix’s Phase 1 trial in pancreatic cancer safe to proceed (FDA)
another step forward for NBTXR3 activated by radiation therapy
May 6, 2020
InteRNA Technologies Receives Regulatory Approval for Initiation of Phase I Clinical Trial of INT-1B3 in Patients with Advanced Solid Tumors
— First-in-human trial will test the safety, pharmacokinetics and preliminary efficacy of microRNA therapeutic candidate INT-1B3 — UTRECHT, The Netherlands–(BUSINESS…
May 5, 2020
Sanofi, Regeneron plan submitting for Libtayo
Sanofi and Regeneron plan to submit this year their product Libtayo, which has shown in a pivotal trial with certain patients with advanced basal cell carcinoma, that it has meaningful and durable responses.
May 5, 2020
Bayer, NeoGenomics launch Test4TRK program to provide free genomic cancer Testing
Bayer to cover testing costs for patients with RAI-refractory (RAI-R) differentiated thyroid carcinoma (DTC) and metastatic colorectal cancer (mCRC) with high microsatellite instability (MSI-H).
April 30, 2020
The Lancet Oncology Publishes Details of UroGen Pharma’s Pivotal OLYMPUS Trial
59% Complete Response in patients with low-grade upper tract urothelial cancer Kaplan-Meier analysis, based on interim data, estimated 12-month durability…